Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUOCINOLONE ACETONIDE vs ACLOVATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Atopic dermatitis,Seborrheic dermatitis,Psoriasis,Eczema,Lichen planus,Lichen simplex chronicus,Discoid lupus erythematosus,Otitis externa (otic solution),Corticosteroid-responsive dermatoses
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Terminal elimination half-life is approximately 1.3-1.5 hours following topical application; after systemic absorption (oral or injection), half-life is 1.5-2.0 hours, necessitating multiple daily dosing for sustained effect.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Primarily hepatic via cytochrome P450 enzymes (CYP3A4) to inactive metabolites; also undergoes local metabolism in skin.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Primarily hepatic metabolism with renal excretion of metabolites (approximately 80% renal, 20% biliary/fecal). Less than 1% excreted unchanged in urine.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
0.2-0.3 L/kg in adults; distributes extensively into tissues with higher concentrations in skin and synovial spaces after local administration.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Topical: very low systemic absorption (approximately 1-2% through intact skin, up to 10-20% through damaged skin or with occlusion); oral: 20-40% due to first-pass metabolism; intra-articular: nearly 100% locally with minimal systemic exposure.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
No dose adjustment required for renal impairment as systemic absorption is minimal with topical use.
No dose adjustment required. Topical use with minimal systemic absorption.
No dose adjustment required for hepatic impairment due to minimal systemic absorption.
No dose adjustment required. Topical use with minimal systemic absorption.
Topical: Apply sparingly to affected area 2-3 times daily. Limit treatment duration to avoid systemic effects. Use lowest potency formulation; not recommended for prolonged use in children under 2 years.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Use with caution due to increased skin fragility and potential for systemic absorption. Apply sparingly and limit duration. Monitor for cutaneous adverse effects.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No FDA boxed warnings specific to fluocinolone acetonide; however, systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
No FDA black box warning.
HPA axis suppression with prolonged use or application to large areas, occlusive dressings, or damaged skin.,Cushing's syndrome and hyperglycemia may occur with systemic absorption.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.,Local adverse reactions including burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Ophthalmic adverse effects: increased intraocular pressure, cataracts with periorbital use.,Not for ophthalmic use except as specifically indicated (e.g., otic solution).
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Hypersensitivity to fluocinolone acetonide or any component of the formulation,Untreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia, varicella) or parasitic skin infections,Perioral dermatitis,Rosacea
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
No known food interactions. No dietary restrictions required.
No known food interactions with topical Aclovate.
Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimesters: Risk of fetal growth restriction and low birth weight with prolonged or high-dose use. Systemic absorption may occur with extensive application, occlusive dressings, or prolonged use. Risk of adrenal suppression in neonate if used near term in high doses.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Excretion in breast milk is unlikely after topical application, but systemic absorption could occur with extensive use. The M/P ratio is unknown. Caution is advised: avoid application to the breast area before nursing, and use the lowest effective dose for the shortest duration.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use the lowest effective potency and duration. Avoid excessive application, especially on large areas or under occlusive dressings.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
Fluocinolone acetonide is a potent corticosteroid for dermatologic use. Avoid prolonged use on face, intertriginous areas, or under occlusion due to increased systemic absorption and risk of atrophy. For scalp psoriasis, the oil-based solution or shampoo forms may improve compliance. Use limited quantities in children to minimize HPA axis suppression. Discontinue if irritation or sensitization occurs.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
Apply a thin layer only to affected skin areas, avoiding healthy skin.,Do not use on broken skin, open wounds, or infections unless directed.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not cover treated areas with bandages or wraps unless instructed by your doctor.,Do not use for more than 2 consecutive weeks without re-evaluation.,Inform your doctor if you are pregnant, breastfeeding, or have diabetes.,Report any signs of skin thinning, stretch marks, or worsening rash.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
"The combination of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), and fluocinolone acetonide, a corticosteroid, may lead to an increased risk of gastrointestinal (GI) adverse effects, including ulceration and bleeding, due to additive inhibition of prostaglandin synthesis. Additionally, corticosteroids can mask the signs of infection and inflammation, potentially delaying diagnosis of NSAID-induced GI injury. Concomitant use also increases the risk of renal impairment, fluid retention, and electrolyte disturbances, particularly in patients with pre-existing renal dysfunction or heart failure."
"Combined use of fluocinolone acetonide (a topical corticosteroid) and fluoxymesterone (an anabolic androgen) increases the risk of sodium and water retention due to their synergistic mineralocorticoid effects. This can lead to exacerbation of hypertension, edema, and potentially precipitate congestive heart failure in susceptible patients. The effect is dose-dependent and more pronounced with systemic absorption of the topical steroid (e.g., when applied to large areas or broken skin)."
"Icatibant, a bradykinin B2 receptor antagonist used for hereditary angioedema, may theoretically attenuate the anti-inflammatory effects of fluocinolone acetonide, a corticosteroid. Corticosteroids suppress inflammation partly by inhibiting bradykinin production and signaling; blocking bradykinin receptors could paradoxically reduce corticosteroid efficacy. However, direct clinical evidence for this interaction is lacking, and the theoretical risk of decreased therapeutic response to fluocinolone acetonide when used with icatibant remains unconfirmed."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUOCINOLONE ACETONIDE vs ACLOVATE, answered by our medical review team.
FLUOCINOLONE ACETONIDE is a Topical Corticosteroid that works by Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.. ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUOCINOLONE ACETONIDE and ACLOVATE depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUOCINOLONE ACETONIDE is: Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.. The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUOCINOLONE ACETONIDE and ACLOVATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUOCINOLONE ACETONIDE is classified as Category A/B. Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimes. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.